Try

Exelixis Inc.

EXELUnited States

79 filed reports · 513 financial concepts · 2 earnings calls · 0 media appearances

Filed reports

79 reports · Jul 2016 to Jul 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 3 operating metrics, 202 guidance figures.

Report typeReportsFactsPeriods
Current · 8-KSEC EDGAR38148Dec 2018 to Jul 2026
Quarterly · 10-QSEC EDGAR315,320Jul 2016 to Jul 2026
Annual · 10-KSEC EDGAR105,086Dec 2016 to Jan 2026

Documents

PeriodTypePeriod endPublishedFactsSource
FY2027 Q28-KJul 3, 2026Aug 5, 20266Open
FY2027 Q210-QJul 3, 2026Aug 5, 2026347Open
FY2027 Q18-KApr 3, 2026May 5, 20264Open
FY2027 Q110-QApr 3, 2026May 5, 2026209Open
FY2026 Q48-KJan 2, 2026Feb 10, 20261Open
FY202610-KJan 2, 2026Feb 10, 2026817Open
FY2026 Q48-KJan 2, 2026Jan 12, 20264Open
FY2026 Q310-QOct 3, 2025Nov 4, 2025221Open
FY2026 Q38-KOct 3, 2025Nov 4, 20254Open
FY2026 Q210-QJul 4, 2025Jul 28, 2025143Open
FY2026 Q28-KJul 4, 2025Jul 28, 20254Open
FY2026 Q110-QApr 4, 2025May 13, 2025142Open

Financial data

513 concepts · 10,554 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial495 concepts · 9,644 facts · Dec 2012 to Jul 2026

  • Net income loss74 · Dec 2012 to Jul 2026
  • Operating income loss72 · Dec 2014 to Jul 2026
  • Revenue72 · Dec 2014 to Jul 2026
  • Cash and cash equivalents at carrying value65 · Dec 2013 to Jul 2026
  • Comprehensive income net of tax64 · Dec 2012 to Jul 2026
  • Allocated share based compensation expense62 · Dec 2014 to Jul 2026
  • Other nonoperating income expense62 · Dec 2014 to Jul 2026
  • Research and development expense62 · Dec 2014 to Jul 2026
  • Selling general and administrative expense62 · Dec 2014 to Jul 2026
  • Additional paid in capital61 · Dec 2012 to Jul 2026
  • Liabilities61 · Dec 2012 to Jul 2026
  • Retained earnings accumulated deficit61 · Dec 2012 to Jul 2026
  • Depreciation depletion and amortization60 · Dec 2014 to Jul 2026
  • Increase decrease in inventories60 · Dec 2014 to Jul 2026
  • Increase decrease in prepaid deferred expense and other assets60 · Dec 2014 to Jul 2026
  • Net cash provided by used in financing activities60 · Dec 2014 to Jul 2026
  • Net cash provided by used in investing activities60 · Dec 2014 to Jul 2026
  • Net cash provided by used in operating activities60 · Dec 2014 to Jul 2026
  • Other noncash income expense60 · Dec 2014 to Jul 2026
  • Payments to acquire property plant and equipment60 · Dec 2014 to Jul 2026
  • Share based compensation60 · Dec 2014 to Jul 2026
  • Earnings per share basic59 · Jan 2016 to Jul 2026
  • Earnings per share diluted59 · Jan 2016 to Jul 2026
  • Income tax expense benefit59 · Dec 2014 to Jul 2026

Product4 concepts · 504 facts · Jan 2016 to Jul 2026

  • Revenue419 · Jan 2016 to Jul 2026
  • Number of products that entered in the commercial marketplace58 · Dec 2016 to Jan 2025
  • Resulting From Discovery Efforts21 · Sep 2023 to Jul 2026
  • Revenue not from contract with customer6 · Mar 2019 to Oct 2020

Geography2 concepts · 154 facts · Dec 2016 to Jul 2026

  • Revenue153 · Dec 2016 to Jul 2026
  • Operating lease and other financing lease1 · Dec 2018

Guidance5 concepts · 154 facts · Feb 2019 to Aug 2026

  • Effective Tax Rate Guidance74 · Feb 2019 to Aug 2026
  • Revenue Guidance66 · Jan 2020 to Aug 2026
  • Revenue Guidance (Net product revenues)10 · Jan 2021 to Aug 2026
  • Effective Tax Rate Guidance (Adjusted (non-GAAP))2 · Apr 2024
  • Revenue Guidance (Adjusted (non-GAAP))2 · Apr 2024

Segment7 concepts · 98 facts · Dec 2022 to Jul 2026

  • Cost of goods and services sold (US GAAP)14 · Dec 2022 to Jul 2026
  • Income tax expense benefit14 · Dec 2022 to Jul 2026
  • Interest income other14 · Dec 2022 to Jul 2026
  • Net income loss14 · Dec 2022 to Jul 2026
  • Reportable Segment14 · Dec 2022 to Jul 2026
  • Revenue14 · Dec 2022 to Jul 2026
  • Segment reporting other item amount14 · Dec 2022 to Jul 2026

Segments

756 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or servicesrt:ProductOrServiceAxis19 members · 481 facts

  • Cabometyx47 · Dec 2016 to Jul 2026
  • Collaboration47 · Dec 2016 to Jul 2026
  • Cometriq47 · Dec 2016 to Jul 2026
  • License47 · Dec 2016 to Jul 2026
  • Product47 · Dec 2016 to Jul 2026
  • Product Gross47 · Dec 2016 to Jul 2026
  • Product Sales Discounts And Allowances40 · Dec 2017 to Jul 2026
  • Service40 · Dec 2018 to Jul 2026
  • Products Derived From Other Compounds30 · Jan 2020 to Jul 2026
  • Resulting From Discovery Efforts30 · Sep 2019 to Jul 2026
  • Other Collaboration12 · Dec 2016 to Sep 2019
  • Researchand Development12 · Dec 2016 to Sep 2019
  • Sales Discounts And Allowances12 · Dec 2016 to Sep 2019
  • Products Derived From Cabozantinib9 · Sep 2019 to Apr 2021
  • Collaboration License3 · Dec 2017 to Jan 2020
  • Collaboration Other3 · Dec 2017 to Jan 2020
  • Collaboration Research And Development Service3 · Dec 2017 to Jan 2020
  • Products Derivedfrom Cabozantinib3 · Dec 2018 to Mar 2019
  • Commercial Presence In Markets Worldwide2 · Dec 2018 to Mar 2019

Statement geographicalsrt:StatementGeographicalAxis4 members · 142 facts

  • Europe47 · Dec 2016 to Jul 2026
  • JP47 · Dec 2016 to Jul 2026
  • US47 · Dec 2016 to Jul 2026
  • South San Francisco California1 · Dec 2018

Statement business segments1 member · 98 facts

  • Reportable98 · Dec 2022 to Jul 2026

Product or serviceus-gaap:ProductOrServiceAxis4 members · 23 facts

  • Cabometyx7 · Jan 2016 to Jun 2018
  • Cometriq7 · Jan 2016 to Jun 2018
  • Products Derivedfrom Cabozantinib5 · Dec 2016 to Jun 2018
  • Product4 · Mar 2017 to Jun 2018

Statement geographicalus-gaap:StatementGeographicalAxis3 members · 12 facts

  • Europe4 · Mar 2017 to Jun 2018
  • JP4 · Mar 2017 to Jun 2018
  • US4 · Mar 2017 to Jun 2018

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Earnings-release commentary161 claims from 10 reports · Sep 2024 to Jul 2026
  • Management discussion (MD&A) commentary169 claims from 8 reports · Sep 2024 to Jul 2026
  • Risk-factor changes14 claims from 1 reports · Jan 2026
  • Risk factors67 risks from 2 annual reports · 2025 to 2026

Earnings calls

2 calls · May 2026 to Aug 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q2Aug 5, 2026
  • FY2026 Q1May 5, 2026

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.

Exelixis Inc. (EXEL) data · FactIQ